Clinical Trials Using Osimertinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Osimertinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 27
1 2 Next >

  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1189 locations

  • Osimertinib with or without Bevacizumab in Treating Patients with EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

    This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with or without bevacizumab may work better in treating patients with non-small cell lung cancer.
    Location: 14 locations

  • Osimertinib and Navitoclax in Treating Patients with EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

    This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 13 locations

  • Osimertinib and Necitumumab in Treating Patients with EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

    This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.
    Location: 9 locations

  • Dacomitinib and Osimertinib in Treating Patients with Metastatic EGFR Mutant Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of dacomitinib and osimertinib in treating patients with EGFR mutant non-small cell lung cancer that has spread to other places in the body. Dacomitinib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Osimertinib, Carboplatin, Cisplatin, and Etoposide in Treating Patients with Metastatic Non-small Cell Lung Cancer with EGFR, RB1, and P53 Mutations

    Mutations are changes in DNA, the genetic material that serves as the body’s instruction book. Some of genetic mutations result in uncontrolled cellular replication and subsequently tumor formation. This phase I trial studies the side effects of osimertinib, carboplatin, cisplatin, and etoposide in treating patients with EGFR, RB1, and P53 mutant non-small cell lung cancer that has spread to other places in the body. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, cisplatin, or etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving osimertinib, carboplatin, cisplatin, and etoposide may work better at treating non-small cell lung cancer.
    Location: 7 locations

  • A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.

    This is a Phase 1 / 1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in subjects with advanced solid tumors. Enrollment is closed for Arms A and D.
    Location: 6 locations

  • Oleclumab (MEDI9447) EGFRm NSCLC Novel Combination Study

    The objective of this study is to investigate the safety, tolerability and antitumor activity of novel combination therapies administered in subjects with advanced EGFRm NSCLC
    Location: 7 locations

  • An Open-Label Phase 1 / 2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Location: 5 locations

  • Niraparib and Osimertinib in Treating Patients with Stage IV EGFR-Mutated Non-small Cell Lung Cancer

    This phase I trial studies the best dose of niraparib when given together with osimertinib in treating patients with stage IV EGFR-mutated non-small cell lung cancer. Niraparib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Niraparib is a type of drug called a “PARP inhibitor”, which blocks deoxyribonucleic acid (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. Osimertinib is an inhibitor of the epidermal growth factor receptor (EGFR). Osimertinib blocks mutated EGFR, which may cause tumor regression (when tumor starts to shrink) and prevent the spread of cancer.
    Location: 4 locations

  • A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

    A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
    Location: 3 locations

  • G1T38, a CDK 4 / 6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

    This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer. The study is an open-label design, consists of 2 parts: safety, pharmacokinetic, and dose-finding portion (Part 1), and randomized portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 144 patients will be enrolled in the study.
    Location: 3 locations

  • Osimertinib and Selumetinib in Treating Participants with Stage IV EGFR Mutant Non-Small Cell Lung Cancer

    This phase II trial studies how well osimertinib and selumetinib work in treating participants with stage IV EGFR mutant non-small cell lung cancer. Osimertinib and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Osimertinib and Gefitinib in Treating Patients with EGFR Mutant Stage IV Non-small Cell Lung cancer

    This randomized phase I / II trial studies the side effects and best dose of osimertinib when given together with gefitinib in treating patients with EGFR mutant stage IV non-small cell lung cancer. Osimertinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Sapanisertib and Osimertinib in Treating Patients with Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

    This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Osimertinib in Treating Patients with Stage IV EGFR-Mutant Non-small Cell Lung Cancer

    This phase II trial studies how well osimertinib works in treating patients with stage IV non-small cell lung cancer who are positive for EGFR mutations. The EGFR gene produces a protein that helps cells divide. Specific changes or mutations in the genetic information can cause abnormal cell division and lead to lung cancer. Patients who have non-small cell lung cancer with an EGFR gene mutation can be treated by drugs called EGFR tyrosine kinase inhibitors. EGFR tyrosine kinase inhibitors such as osimertinib, may stop (or “inhibit”) the effect of the mutation in the EGFR gene and may stop the growth of tumor cells.
    Location: 2 locations

  • Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients with EGFR-Mutated Stage IV Non-small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of glutaminase inhibitor CB-839 hydrochloride, and to see how well it works when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Glutaminase inhibitor CB-839 hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Osimertinib and Stereotactic Body Radiation Therapy in Treating Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer

    This phase II trial studies the how well osimertinib works when given together with stereotactic body radiation therapy in treating patients with EGFR mutant non-small cell lung cancer that has spread to other places in the body. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving osimertinib and stereotactic body radiation therapy may work better in treating patients with advanced non-small lung cancer.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Osimertinib and Stereotactic Radiosurgery in Treating Patients with Brain Metastases from EGFR-Positive Non-Small-Cell Lung Cancer

    This phase I trial studies the side effects, best dose, and how well osimertinib works when used in combination with stereotactic radiosurgery in treating patients with EGFR-positive non-small cell lung cancer that has spread to the brain. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving osimertinib with stereotactic radiosurgery may work better in treating patients with brain metastases from EGFR-positive non-small cell lung cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Osimertinib in Treating Participants with Stage IV Non-Small Cell Lung Cancer with Uncommon EGFR Mutations

    This phase II trial studies how well osimertinib works in treating participants with stage IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Osimertinib in Treating Participants with Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer before Surgery

    This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA EGFR-mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.
    Location: 3 locations

  • Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer with EGFR Mutations

    This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving osimertinib, surgery, and radiation therapy may work better at treating non-small cell lung cancer with EGFR mutations.
    Location: 3 locations

  • DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

    This study has two parts: dose escalation and dose expansion. The primary objectives are: - For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with osimertinib in the study population and to determine the recommended dose for expansion of DS-1205c when combined with osimertinib in the study population - For Dose Expansion, to assess the safety and tolerability of DS-1205c when combined with osimertinib in the study population In Dose Escalation, after a 7-day run in period (Cycle 0), there will be 21-day cycles (Cycle 1 onward). In Dose Expansion, there will be 21-day cycles. The number of treatment cycles is not fixed in this study. Participants will continue study treatment for 36 months unless they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity).
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

    Background: Some non-small-cell lung cancers (NSCLC) have a mutation in a gene that makes a protein called EGFR. This particular cancer can be treated with certain drugs such as Erlotinib (Tarceva), Gefitinib (Iressa) and Osimertinib (Tagrisso). But many tumors become resistant to these drugs because of a second mutation. Researchers want to test if adding local ablative therapy (LAT) extends the benefits of the drug, Osimertinib. LAT can include techniques such as surgery, radiofrequency ablation, cryotherapy or radiation therapy. Objective: To test if re-taking osimertinib after LAT is safe, tolerable, and effective for people whose NSCLC has progressed after initial treatment with osimertinib. Eligibility: Adults ages 18 and older with certain types of NSCLC. Participants will be divided into various groups as described below. Design: Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests Tumor scans Eye exam Review of tumor sample. Participants will take the study drug by mouth once a day. They will continue until they can no longer tolerate it or their disease worsens. They will keep a dosage diary. All participants will start each 21-day course with physical exam; blood, urine, and saliva tests; and electrocardiogram. They will have scans every 6 weeks and echocardiogram every 3 months. Groups 1 and 2 will: Start osimertinib right away. Have LAT if their disease gets worse and is suitable for LAT. If LAT cannot be performed or LAT consists of a procedure other than surgery, a tumor biopsy will be performed. Re-start osimertinib after LAT, or other treatments if not suitable for LAT. Group 3 will: Have LAT. If LAT consists of a procedure other than surgery, a tumor biopsy will be performed. Start osimertinib after LAT. After participants stop taking the drugs, they will have a final visit. This will include: Medical history Physical exam Heart and blood tests Participants will be called every year for follow-up.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

    Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
    Location: 4 locations


1 2 Next >